All In Biotech

Drug Trial Radar · NCT04210115

Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)

A Randomized, Double-blind, Placebo-controlled Phase 3 Trial of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Receiving Concurrent Definitive Chemoradiotherapy (KEYNOTE 975)

Last checked: Nov 20, 2026Latest source record: Oct 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 703 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

703

Actual

Start

Feb 28, 2020

Primary completion

Jan 21, 2026

Study completion Jun 26, 2026

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Dec 24, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the efficacy and safety of treatment with definitive chemoradiotherapy (dCRT) + pembrolizumab (MK-3475) compared to treatment with dCRT + placebo with respect to Event-free Survival (EFS) and Overall Survival (OS) in: * participants whose tumors express Programmed Death-Ligand 1 (PD-L1) Combined Positive Score (CPS) ≥10 * participants whose tumors express PD-L1 CPS ≥1 * all participants The primary study hypotheses are that dCRT+ pembrolizumab is better than dCRT + placebo with respect to: * EFS in participants whose tumors express PD-L1 CPS ≥10 * EFS in participants whose tumors express PD-L1 CPS ≥1 * EFS in all participants * OS in participants whose tumors express PD-L1 CPS ≥10 * OS in participants whose tumors express PD-L1 CPS ≥1 * OS in all participants

Conditions

  • Esophageal Squamous Cell Carcinoma (ESCC)
  • Gastroesophageal Junction Carcinoma (GEJC)
  • Esophageal Adenocarcinoma (EAC)

Interventions

  • pembrolizumabBiological

    IV infusion

  • placeboDrug

    IV infusion

  • cisplatinDrug

    IV infusion

  • 5-FUDrug

    IV infusion

  • radiotherapyRadiation

    external radiation

  • leucovorinDrug

    IV infusion

  • levoleucovorinDrug

    IV infusion

  • oxaliplatinDrug

    IV infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Event-free Survival (EFS)Time frame: Up to ~60 months
  2. Overall Survival (OS)Time frame: Up to ~72 months

Locations

170 sites in 27 countries. Site status is shown where the registry gives one.

  • MemorialCare Health System - Long Beach Medical Center-Oncology ( Site 0691)

    Long Beach, California

  • Columbus Regional Research Institute ( Site 0047)

    Columbus, Georgia

  • University of Kansas Cancer Center ( Site 0023)

    Westwood, Kansas

  • Cancer Center of Kansas ( Site 0058)

    Wichita, Kansas

  • University Medical Center ( Site 0035)

    New Orleans, Louisiana

  • Greater Baltimore Medical Center ( Site 0031)

    Baltimore, Maryland

  • Dana Farber Cancer Center ( Site 0034)

    Boston, Massachusetts

  • Henry Ford Hospital ( Site 0685)

    Detroit, Michigan

  • University of Missouri ( Site 0688)

    Columbia, Missouri

  • Renown Regional Medical Center ( Site 0706)

    Reno, Nevada

  • Rutgers Cancer Institute of New Jersey ( Site 0695)

    New Brunswick, New Jersey

  • Weill Cornell Medical College ( Site 0053)

    New York, New York

  • Stephenson Cancer Center ( Site 0044)

    Oklahoma City, Oklahoma

  • Oregon Health & Science University Center for Health & Healing 2- CHH2 ( Site 0060)

    Portland, Oregon

  • Allegheny Health Network ( Site 0042)

    Pittsburgh, Pennsylvania

  • Thompson Cancer Survival Center ( Site 0696)

    Knoxville, Tennessee

  • Utah Cancer Specialists ( Site 0697)

    Salt Lake City, Utah

  • Cancer Care Northwest - Spokane Valley ( Site 0036)

    Spokane Valley, Washington

  • University of Wisconsin Hospital and Clinics ( Site 0033)

    Madison, Wisconsin

  • Hospital Municipal de Gastroenterologia Dr. Bonorino Udaondo ( Site 0066)

    Buenos Aires, Argentina

  • CEMIC ( Site 0064)

    Buenos Aires, Argentina

  • Instituto Medico Alexander Fleming ( Site 0063)

    Buenos Aires, Buenos Aires F.D., Argentina

  • Fundacion Favaloro ( Site 0061)

    Ciudad de Buenos Aires, Buenos Aires F.D., Argentina

  • UCL Saint Luc ( Site 0162)

    Brussels, Bruxelles-Capitale, Region de, Belgium

  • UZ Gent ( Site 0163)

    Ghent, Oost-Vlaanderen, Belgium

  • UZ Leuven ( Site 0161)

    Leuven, Vlaams-Brabant, Belgium

  • AZ Delta ( Site 0165)

    Roeselare, West-Vlaanderen, Belgium

  • Instituto do Cancer do Estado de Sao Paulo - ICESP ( Site 0081)

    São Paulo, Brazil

  • ONCOSITE - Centro de Pesquisa Clinica em Oncologia ( Site 0088)

    Ijuí, Rio Grande do Sul, Brazil

  • Hospital Nossa Senhora da Conceicao ( Site 0087)

    Porto Alegre, Rio Grande do Sul, Brazil

  • Clinica de Oncologia Reichow ( Site 0085)

    Blumenau, Santa Catarina, Brazil

  • Cross Cancer Institute ( Site 0010)

    Edmonton, Alberta, Canada

  • CancerCare Manitoba ( Site 0002)

    Winnipeg, Manitoba, Canada

  • The Ottawa Hospital - Cancer Care ( Site 0008)

    Ottawa, Ontario, Canada

  • Sunnybrook Research Institute ( Site 0012)

    Toronto, Ontario, Canada

  • Princess Margaret Cancer Centre ( Site 0011)

    Toronto, Ontario, Canada

  • Centre Hospitalier de l Universite de Montreal - CHUM ( Site 0005)

    Montreal, Quebec, Canada

  • Centro Investigación del Cáncer James Lind ( Site 0106)

    Temuco, Araucania, Chile

  • Centro de Investigacion y desarrollo Oncologico SpA - CIDO SpA ( Site 0103)

    Temuco, Araucania, Chile

  • Hospital Regional de Concepcion ( Site 0105)

    Concepción, Biobio, Chile

Showing 40 of 170 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.